Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1997; 78(01): 334-338DOI: 10.1055/s-0038-1657548 Oral contraceptives and thrombotic disease Schattauer GmbH Stuttgart Oral Contraceptives and Myocardial Infarction: New Evidence Leaves Unanswered Questions Margaret Thorogood London School of Hygiene & Tropical Medicine, London, UK › Author AffiliationsRecommend Article Abstract PDF Download Buy Article PDF (696 kb) References References 1 Rosenberg L, Palmer JR, Leso SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990; 131: 1009-1016 2 Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol 1991; 98: 1245-1253 3 Jensen G, Nyboe J, Appleyard M, Schnohr P. Risk factors for acute myocardial infarction in Copenhagen 11: Smoking alcohol intake physicalctivity obesity, oral contraception, diabetes, lipids, and blood pressure. Eur Heart J 1991; 12: 298-308 4 D’Avanzo B, La VecchiaC, Negri E, Parazzini F, Franceschi S. Oral contraceptive use and risk of myocardial infarction: an Italian case control study. J Epidemiol Community Health 1994; 48: 324-325 5 Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher R, Thorogood M. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996; 312: 88-90 6 Sidney S, Petitti DB, Quesenberry CP, Klatskey AL, Ziel HK, Wolf S. Myocardial Infarction in Users of Low-Dose Oral Contraceptives. Obstet Gynecol 1996; 88: 939-944 7 Slone D, Shapiro S, Kaufman DW, Rosenberg L, Mietinnen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981; 305: 420-424 8 Ananijevic-Panday J, Vlajinac H. Myocardial infarction in young women with reference to oral contraceptive use. Internat J Epidemiol 1989; 18: 585-588 9 Poulter N et al for the writing committee of the World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multi centre case-control study. Lancet 1995; 346: 1575-1582 10 Meirik O et al on behalf of the World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptive on venous thromboembolic disease. Lancet 1995; 326: 1575-1582 11 Spitzer WO, Lewis MA, Heinemann JA, Thorogood M, MacRae KD. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Br Med J 1996; 312: 38-48 12 Bloemenkamp KWM, Rosendaal FR, Helmerhurst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995; 346: 1593-1596 13 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with different progestogen components. Lancet 1995; 346: 1589-1593 14 Jick H, Jick SS, Myers W. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 1996; 347: 627-628
